Abstract
T cell immune responses play a critical role in preventing and treating malignant tumors. The most effective way for stimulating potent T cell immunity is by genetic immunization with recombinant viral vectors. Recombinant lentivector has recently been studied as antigen delivery vehicle for stimulating potent T cell responses. Studies showed that lentivector immunization can induce remarkably potent and durable CD8 T cell responses possibly because of their high efficiency of transducing dendritic cells (DCs) and persistent antigen presentation. In this brief review, we summarized the recent findings on the basic mechanistic studies, especially on the role of DC subsets in lentivector immunization, and the potential applications of using lentivector immunization for tumor immunotherapy in preclinical animal models.
Keywords: Recombinant lentivector, dendritic cells, tumor immunotherapy, genetic immunization
Current Cancer Therapy Reviews
Title: Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Volume: 7 Issue: 4
Author(s): Qifeng Zhou and Yukai He
Affiliation:
Keywords: Recombinant lentivector, dendritic cells, tumor immunotherapy, genetic immunization
Abstract: T cell immune responses play a critical role in preventing and treating malignant tumors. The most effective way for stimulating potent T cell immunity is by genetic immunization with recombinant viral vectors. Recombinant lentivector has recently been studied as antigen delivery vehicle for stimulating potent T cell responses. Studies showed that lentivector immunization can induce remarkably potent and durable CD8 T cell responses possibly because of their high efficiency of transducing dendritic cells (DCs) and persistent antigen presentation. In this brief review, we summarized the recent findings on the basic mechanistic studies, especially on the role of DC subsets in lentivector immunization, and the potential applications of using lentivector immunization for tumor immunotherapy in preclinical animal models.
Export Options
About this article
Cite this article as:
Zhou Qifeng and He Yukai, Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs, Current Cancer Therapy Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339411797642588
DOI https://dx.doi.org/10.2174/157339411797642588 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Metabolomic and Imaging: A Literature Review
Current Medical Imaging Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy